Vaxil Bio Stock Today
| VXL Stock | CAD 0.01 0.00 0.00% |
Performance0 of 100
| Odds Of DistressOver 86
|
Vaxil Bio is selling for under 0.01 as of the 20th of September 2024; that is No Change since the beginning of the trading day. The stock's lowest day price was 0.01. Vaxil Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Vaxil Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of October 2022 and ending today, the 20th of September 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Vaxil Bio Ltd., an immunotherapy biotech company, engages in the research and development of immunotherapies for cancer and infectious diseases in Israel. The company was founded in 2006 and is headquartered in Toronto, Canada. VAXIL BIO is traded on TSX Venture Exchange in Canada.. The company has 136.98 M outstanding shares of which 3.73 K shares are at this time shorted by private and institutional investors with about 1.77 days to cover all short positions. More on Vaxil Bio
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Vaxil Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Vaxil Bio's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Vaxil Bio or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Chairman | David Goren | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
Vaxil Bio's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Vaxil Bio's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsVaxil Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vaxil Bio's financial leverage. It provides some insight into what part of Vaxil Bio's total assets is financed by creditors.
| |||||
Vaxil Bio (VXL) is traded on TSX Venture Exchange in Canada and employs 3 people. Vaxil Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.37 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vaxil Bio's market, we take the total number of its shares issued and multiply it by Vaxil Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Vaxil Bio classifies itself under Biotechnology sector and is part of Health Care industry. The entity has 136.98 M outstanding shares of which 3.73 K shares are at this time shorted by private and institutional investors with about 1.77 days to cover all short positions.
Vaxil Bio has accumulated about 307 K in cash with (561 K) of positive cash flow from operations.
Check Vaxil Bio Probability Of Bankruptcy
Ownership AllocationVaxil Bio shows a total of 136.98 Million outstanding shares. Vaxil Bio has 8.16 % of its outstanding shares held by insiders and 0.01 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Vaxil Ownership Details
Vaxil Stock Against Markets
| VXL | 0.00 |
|
| Competition | Refresh |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Vaxil Bio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Manager Now
Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital |
| All Next | Launch Module |
Additional Tools for Vaxil Stock Analysis
When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.